U.S. Capital Wealth Advisors LLC Purchases 3,034 Shares of Johnson & Johnson (NYSE:JNJ)

U.S. Capital Wealth Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.7% during the third quarter, HoldingsChannel reports. The fund owned 115,054 shares of the company’s stock after buying an additional 3,034 shares during the quarter. Johnson & Johnson comprises about 1.0% of U.S. Capital Wealth Advisors LLC’s portfolio, making the stock its 14th largest holding. U.S. Capital Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $18,795,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Red Wave Investments LLC raised its stake in Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock worth $530,000 after buying an additional 59 shares during the period. Argus Investors Counsel Inc. increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after purchasing an additional 61 shares in the last quarter. Alta Capital Management LLC increased its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after purchasing an additional 61 shares in the last quarter. Paces Ferry Wealth Advisors LLC increased its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after purchasing an additional 62 shares in the last quarter. Finally, Mason & Associates Inc increased its holdings in Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after purchasing an additional 62 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.74 on Monday. The stock has a fifty day simple moving average of $176.14 and a two-hundred day simple moving average of $171.20. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The firm has a market cap of $441.17 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 3.19 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock worth $40,960,735 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on JNJ shares. Morgan Stanley decreased their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Atlantic Securities decreased their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Sanford C. Bernstein reduced their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James reduced their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Finally, Bank of America reduced their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.